Citius Oncology, Inc. CTOR

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
27/100
Developing

Ranked against 90 peers in Drug Manufacturers - Specialty & Generic

About Citius Oncology, Inc.

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron … Full CTOR analysis →

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.20), raising refinancing risk.
  • Liquidity Concerns Liquidity is concerning (score 0.07), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where CTOR ranks in Drug Manufacturers - Specialty & Generic

Citius Oncology, Inc. ranks #69 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score — the top 76%. The widest moat in the group is Zoetis Inc. (ZTS) at 85/100.

# Company Moat score Rating
65 Sunshine Biopharma Inc. SBFM 31/100 Developing
66 China Pharma Holdings, Inc. CPHI 29/100 Developing
67 Flora Growth Corp. FLGC 29/100 Developing
68 Avadel Pharmaceuticals plc AVDL 27/100 Developing
69 Citius Oncology, Inc. CTOR 27/100 Developing
70 Aquestive Therapeutics, Inc. AQST 26/100 Developing
71 China SXT Pharmaceuticals, Inc. SXTC 26/100 Developing
72 Petros Pharmaceuticals, Inc. PTPI 25/100 Developing
73 Gelteq Limited GELS 23/100 Weak

See every Pharma / Mature Biotech company ranked by moat score →

How CTOR scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 34 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 15 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding CTOR's moat

What is Citius Oncology, Inc.'s moat score?

Citius Oncology, Inc. (CTOR) scores 27 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #69 of 91 scored companies in Drug Manufacturers - Specialty & Generic, the top 76%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 90 companies in Drug Manufacturers - Specialty & Generic. Its strongest defense is Capital Efficiency (34/100) and its weakest is Resilience (15/100).

How does Citius Oncology, Inc. compare with other Drug Manufacturers - Specialty & Generic companies?

Citius Oncology, Inc. ranks #69 of 91 scored companies in Drug Manufacturers - Specialty & Generic by moat score. The widest moat in Drug Manufacturers - Specialty & Generic is Zoetis Inc. (ZTS) at 85/100. The companies ranked closest are Avadel Pharmaceuticals plc (AVDL) at 27 just above it and Aquestive Therapeutics, Inc. (AQST) at 26 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 90 companies in Drug Manufacturers - Specialty & Generic. The defenses are then weighted to produce the overall score out of 100.

Why is Citius Oncology, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Citius Oncology, Inc.?

The Corporate Default template measures 6 defenses, and CTOR scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (34), Resilience (15), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000